3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Thoracic
1
Conditions
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Carboplatin
351
pembrolizumab
327
Pemetrexed
249
Cisplatin
221
Paclitaxel
149
Nivolumab
139
durvalumab
134
Docetaxel
112
osimertinib
111
atezolizumab
107
Specimen Handling
91
Radiotherapy
89
Drug Therapy
87
Magnetic Resonance Spectroscopy
78
Etoposide
78
Radiosurgery
74
Gemcitabine
72
Ipilimumab
55
130-nm albumin-bound paclitaxel
54
Bevacizumab
53
cemiplimab
47
tislelizumab
46
Blood Specimen Collection
43
Cetuximab
35
Taxes
34
Injections
33
Biopsy
33
Standard of Care
32
Platinum
32
Immunoglobulin G
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AZD3759
×
Thoracic
×
1 year
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled